• AMLSG 16-10: long-term benefits of midostaurin for FLT3-ITD-mutated AML

    The final trial results showed that younger and older patients with FLT3-ITD-mutated AML benefitted from adding midostaurin to intensive chemotherapy.

  • iStopMM: smouldering MM highly prevalent in general population

    The large, population-based study showed prevalence in 40 years+ patients. Approximately 1 out of 3 smouldering MM patients may progress towards MM.

  • MajesTEC-1: teclistamab efficacious in heavily pre-treated MM

    Teclistamab was safe and efficacious in relapsed/refractory multiple myeloma patients. Phase 1/2 trial showed durable and deepening responses.

  • Reduced risk of Alzheimer’s disease in CHIP carriers

    CHIP was related to decreased risk of AD and its neuropathological changes. Mutated haematopoietic stem cells were detected in the brains of CHIP carriers.

  • Novel triplet regimen may benefit heavily pre-treated FLT3-mutated AML patients

    A quizartinib, venetoclax and decitabine combo was highly active in patients with relapsed/refractory FLT3-ITD-mutated acute myeloid leukaemia.

  • JAK2V617F allele frequency predicts venous events in polycythaemia vera

    A JAK2V617F variant with an allele frequency of over 50% is associated with a higher risk of venous thrombosis in patients with polycythaemia vera (PV).

  • Encouraging results of novel triplet combination for AML

    Cladribine plus low-dose cytarabine plus venetoclax alternated with 5-azacytidine plus venetoclax showed encouraging efficacy in newly diagnosed AML patients.

  • ATLAS-INH: impressive results of fitusiran for haemophilia

    Treatment with fitusiran for prophylaxis resulted in a lower rate of bleeding events and improved health quality of life in haemophilia A or B patients with inhibitors.

  • Persistent disparities in ALL health outcomes

    Significant disparities in health outcomes were observed across race, ethnicity, and socioeconomic status (SES) in patients with acute lymphoblastic leukaemia (ALL).

  • Comparable effectiveness of CPX-351 and HMA plus venetoclax in older AML patients

    CPX-351 therapy did not result in different overall survival (OS) outcomes or response rates than venetoclax plus HMA therapy in patients with acute myeloid leukaemia (AML) between 60 and 75 years of age.

  • Promising results: Tacrolimus plus dexamethasone in immune thrombocytopenia

    The combination regimen of low-dose tacrolimus plus high-dose dexamethasone provides benefits over high-dose dexamethasone monotherapy in patients with immune thrombocytopenia (ITP), promising first-line treatment for patients with ITP.

  • Talquetamab plus daratumumab for multiple myeloma

    The dual therapy demonstrated durable and deep responses in heavily pre-treated patients with refractory MM. The combination regimen was tolerable and did not show overlapping toxicity. It is therefore a promising option for treating patients with MM.

  • Benefits of eprenetapopt plus azacytidine for TP53-mutant MDS and oligoblastic AML

    Combination therapy of eprenetapopt plus azacytidine showed efficacy and safety in patients with TP53-mutant myelodysplastic syndrome and oligoblastic acute myeloid leukaemia.

  • TNF inhibitor for immune-mediated inflammatory disease increases risk of new-onset psoriasis

    Immune-mediated inflammatory disease treated with a TNFα inhibitor had a 2-fold increased risk of new-onset psoriasis compared with conventional therapy.

  • Secukinumab also tolerable in paediatric psoriasis patients

    Pooled safety analyses of 2 phase 3 trials revealed similar tolerability of the IL-17A inhibitor secukinumab in children and adolescents with moderate-to-severe plaque psoriasis.

  • Digital health: Treating depression via app?

    Digital health apps offer those affected by depression the possibility of supporting psychotherapy. Dr. sc. hm. Gwendolyn Mayer explains what these apps are about, who they are suitable for and how effective they are.

  • Dying with dignity - how can couples say goodbye

    When a person is at the end of their life, it means change. At Heidelberg University Hospital, a team of therapists works with the concept of Dignity Therapy according to Chochinov and expands it to include the aspect of couple relationships.

  • How successful is virtual reality in depression and anxiety disorders therapy?

    The number of mental illnesses worldwide is growing - and with it the need for good therapies. What is the benefit of treating depression and anxiety with virtual reality? Researchers from New Zealand have evaluated studies.

  • Psychosocial late sequelae of the Covid-19 pandemic

    What does the Covid-19 pandemic do to people psychologically? This questions was addressed in a lecture at the University Hospital Jena, Germany.

  • Rheumatism and COVID-19: How safe are TNF inhibitors?

    Most rheumatism drugs can be used safely in SARS-CoV-2 infections. Some even seem to protect against severe cases, but individual drugs were associated with a complicated disease path.

  • 15 |
  • 16 |
  • 17 |
  • 18 |
  • 19 |
  • 20 |
  • 21 |
  • 22 |
  • 23 |
  • 24 |
  • 25 |